Zoetis Inc. $ZTS Shares Bought by Avidian Wealth Enterprises LLC

Avidian Wealth Enterprises LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 39.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 5,296 shares of the company’s stock after buying an additional 1,491 shares during the quarter. Avidian Wealth Enterprises LLC’s holdings in Zoetis were worth $826,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Bogart Wealth LLC boosted its position in Zoetis by 14.5% during the second quarter. Bogart Wealth LLC now owns 41,589 shares of the company’s stock worth $6,486,000 after acquiring an additional 5,260 shares during the last quarter. Stephens Inc. AR lifted its stake in shares of Zoetis by 16.7% during the 2nd quarter. Stephens Inc. AR now owns 129,045 shares of the company’s stock worth $20,125,000 after purchasing an additional 18,483 shares during the period. Calamos Wealth Management LLC boosted its holdings in shares of Zoetis by 1.7% during the second quarter. Calamos Wealth Management LLC now owns 87,147 shares of the company’s stock worth $13,591,000 after purchasing an additional 1,469 shares during the last quarter. Parthenon LLC grew its position in shares of Zoetis by 0.8% in the second quarter. Parthenon LLC now owns 9,485 shares of the company’s stock valued at $1,479,000 after purchasing an additional 75 shares during the period. Finally, Cidel Asset Management Inc. grew its position in shares of Zoetis by 2.4% in the second quarter. Cidel Asset Management Inc. now owns 119,049 shares of the company’s stock valued at $18,566,000 after purchasing an additional 2,735 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.7%

Shares of NYSE ZTS opened at $146.13 on Wednesday. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $189.98. The company has a market cap of $64.76 billion, a P/E ratio of 25.15, a P/E/G ratio of 2.33 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a fifty day moving average price of $148.58 and a 200 day moving average price of $153.55.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the previous year, the firm posted $1.56 earnings per share. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s payout ratio is 34.42%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. UBS Group lowered their target price on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a report on Monday. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average price target of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.